Therapies for obesity, diabetes and related indications
US10660939B2 · kind B2 · utility
0Cited by
30References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 3, 2017 |
| Grant date | May 26, 2020 |
| Priority date | — |
| Expiry date | Jan 28, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to methods, uses, compositions and formulations including a melanocortin receptor-4 agonist and a glucagon-like peptide-1 receptor agonist for treatment of obesity, diabetes, metabolic syndrome and related indications, diseases or disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.